Table 2:
Prevalence for methylation of genes in sputum samples from cancer-free smokers (CFS) with or without COPD and smokers with lung adenocarcinoma (LUAD)
| Genes | Methylated | ||||
|---|---|---|---|---|---|
| COPD status of CFS, n (%) | LUAD, n (%) | OR (95% CI)†† (CFS vs. LUAD) | |||
| Non-COPD (n = 76) | COPD (n = 32) | Total (n = 108) | (n = 29) | ||
| CCNA1 | 5/76 (7%) | 3/32 (9%) | 8/108 (7%) | 0/29 (0%) | ND |
| SNCA | 21/76 (28%) | 7/32 (22%) | 28/108 (26%) | 15/29 (52%) | 3.06 (1.3—7.1) |
| ZNF549† | 9/75 (12%) | 7/31 (23%) | 16/106 (15%) | 11/29 (38%) | 3.44 (1.4 – 8.6) |
*
Statistically significant differences are shown in bold.
†
ZNF549 assay failed for 2 samples, one non-COPD and one COPD.
††
The differences in the methylation of each of the three genes is compared between total CFS (COPD and non-COPD samples combined) versus LUAD. ND (not determined).